Evidence map›Paper›PMID 42067999›Full record

ArticleClinical genetics2026

Discovery of PHB1 as a Novel Candidate Gene in Dominant Optic Atrophy.

Marija Volk, Aleš Maver, Martina Jarc Vidmar, Nuša Trošt, Tanja Višnjar, Ana Fakin, Lea Kovač, Maja Šuštar Habjan, Lucija Malinar, Sanja Petrović Pajić and 4 more

Abstract read
In one paragraph

Article in Clinical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marija VolkClinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Aleš MaverClinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.ORCID 0000-0002-9826-0534
Martina Jarc VidmarFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Nuša TroštClinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Tanja VišnjarClinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Ana FakinFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Lea KovačFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Maja Šuštar HabjanEye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Lucija MalinarEye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Sanja Petrović PajićEye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Urška Dragin JermanFaculty of Medicine, Institute of Cell Biology, University of Ljubljana, Ljubljana, Slovenia.
Rok RomihFaculty of Medicine, Institute of Cell Biology, University of Ljubljana, Ljubljana, Slovenia.
Marko HawlinaFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Borut PeterlinClinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.ORCID 0000-0001-7824-4978

Funding

Slovenian Research Agency P3-0108Slovenian Research Agency P3-0326Slovenian Research Agency P3-0333
6 · The paper itself

Abstract

Hereditary optic neuropathies comprise a genetically heterogeneous group of disorders caused by pathogenic variants in mitochondrial and nuclear genes. Despite increasing diagnostic yields, many patients remain without a molecular diagnosis. We report a novel candidate heterozygous variant in the PHB1 (Prohibitin 1) gene in a large family affected by autosomal dominant optic atrophy. A three-generation family with slowly progressive visual acuity loss due to optic neuropathy and an apparent autosomal dominant pattern was clinically characterized and recruited for genetic counseling. Exome sequencing and genome-based linkage mapping were performed, alongside protein modeling and in vitro experiments to obtain functional evidence. Family-based whole-genome linkage mapping identified a heterozygous missense variant, c.440C>T (p.Ser147Phe), in PHB1 in all five affected individuals. The variant substitutes p.Ser147Phe within an evolutionarily conserved alpha-helix domain of PHB1, a mitochondrial protein with multiple roles. In silico modeling suggested that p.Ser147Phe may disrupt PHB1 stability and function through loss of hydrogen bonding, steric hindrance, and altered hydrophobic interactions. In vitro experiments suggested potential alterations in mitochondrial dynamics in variant carriers, including a changed ratio of L-OPA1 to S-OPA1 compared with non-carriers. We present initial evidence that PHB1 is a novel candidate gene potentially associated with dominant optic atrophy or a related mitochondrial disorder. This represents the first report implicating PHB1 in a Mendelian disease. Further studies are required to validate this association.

Indexed as

Genetic Predisposition to DiseaseOptic Atrophy, Autosomal DominantRepressor ProteinsAdultFemaleGenetic Association StudiesGenetic LinkageHumansMaleModels, MolecularMutation, MissensePedigreeProhibitinsPHB protein, humanProhibitinsRepressor Proteins

Identifiers

PMID42067999
PMCPMC13327145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.